References Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ Signaling pathways governing breast cancer stem cells behavior Triple-negative breast cancer: risk factors to potential targets Genetic susceptibility to triple-negative breast cancer Breast cancer stem cells-from origins to targeted therapy Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance CSC Radioresistance: a therapeutic challenge to improve radiotherapy effectiveness in cancer Breast cancer stem cells as drivers of tumor chemoresistance, dormancy and relapse: new challenges and therapeutic opportunities Targeting stem cells in the realm of drug-resistant breast cancer Targeting breast cancer stem cells to overcome treatment resistance Dual or multiple drug loaded nanoparticles to target breast cancer stem cells BRD4 and cancer: going beyond transcriptional regulation Targeting bromodomains: epigenetic readers of lysine acetylation BRD4 regulates self-renewal ability and tumorigenicity of glioma-initiating cells by enrichment in the Notch1 promoter region A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells BRD4 regulates transcription factor DeltaNp63alpha to drive a cancer stem cell phenotype in squamous cell carcinomas Increased PD-L1 expression in acquired cisplatin-resistant lung cancer cells via mir-181a PD-1/PD-L1 pathway: current researches in cancer PD-L1 is overexpressed on breast cancer stem cells through notch3/mTOR axis PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways Combinatorial strategies with PD-1/PD-L1 immune checkpoint blockade for breast cancer therapy: mechanisms and clinical outcomes Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer NF-kappaB and the immune response RelB sustains endocrine resistant malignancy: an insight of noncanonical NF-kappaB pathway into breast cancer progression RELB alters proliferation of human pluripotent stem cells via IMP3- and LIN28-mediated modulation of the expression of IGF2 and other cell-cycle regulators The NF-kappaB pathway and cancer stem cells BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting ‘undruggable’ myc-pathway genes BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy Regulation of sister chromatid cohesion by nuclear PD-L1 Inhibition of NF-kappaB signaling reduces the stemness characteristics of lung cancer stem cells Verteporfin inhibits PD-L1 through autophagy and the STAT1-IRF1-TRIM28 signaling axis, exerting antitumor efficacy Direct transcriptional regulation of RelB by 1alpha,25-dihydroxyvitamin D3 and its analogs: physiologic and therapeutic implications for dendritic cell function Context-specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers Inhibition of nuclear factor-kappab p65 phosphorylation by 3,4-dihydroxybenzalacetone and caffeic acid phenethyl ester Regulation of cancer stem cells by cytokine networks: attacking cancer’s inflammatory roots Discovery of the natural product 3’,4’,7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity Isolation and establishment of human tumor stem cells Cancer stem cell self-renewal as a therapeutic target in human oral cancer Targeting cancer stem cell pathways for cancer therapy Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer Cytokines, breast cancer stem cells (BCSCs) and chemoresistance